PHSA is pleased to present the consolidated Research and Student Education Metrics Report that integrates successes in these areas and reflects PHSA's strength as major Canadian academic health science organization.
Research and student education, together with patient care, represent the integrated tripartite mandate of PHSA, one of the country’s largest academic health science organizations.
Fiscal year 2022/2023 is the fifteenth year that PHSA has published metrics for key research indicators, and the ninth year it has published metrics for student education indicators.
This year’s consolidated report
reflects PHSA’s continuing strength as one of Canada’s largest academic health science organizations and includes:
- a high-level summary highlighting significant impacts and outcomes as well as key trends and developments;
- infographics presenting FY 2022/2023 information at both the PHSA and program level, as well as multi-year trend data for PHSA research;
- Top 3 Achievements by research program; and
- detailed outcomes by reporting entity, including identification of those achieved through intra-PHSA collaboration.
With total external funding of over $190 million, including $7 million for COVID-19 research, PHSA continues to be one of Canada's largest academic health science organizations.
Clinical trial activity remained strong with 706 active clinical trials in FY 2022/23. PHSA continues to actively advance commercialization of research discoveries with IP realized revenue totalling almost $1.8 million. PHSA's overall success rate for CIHR project grants outperformed the national average.
A detailed Research
supplementary report and Student Education
supplementary report for fiscal year 2022/2023 are also available.